HBOT Conversations:
Dr. Paul Harch & Inflammation
Dr. Paul G. Harch, M.D. has used hyperbaric oxygen therapy to treat more than 100 different conditions, including stroke, dementia, autism, and traumatic brain injury. His goal is to help his patients get their lives back using hyperbaric oxygen therapy.
He is the author of The Oxygen Revolution and is considered an International expert and pioneer in the field of Hyperbaric Oxygen Therapy (HBOT). His informative, and comprehensive guide on HBOT has helped countless souls better understand what HBOT is and how it directly affects the body at the genetic level.
This episode on Inflammation is the first in a 9 episode series that will be released weekly with Dr. Harch.
Watch the Podcast
HBOT News podcast host, Edward di Girolamo, talks with special guest and HBOT expert, Dr. Paul G. Harch, MD. This is the first of nine episodes with Dr. Harch examining the God-given miracle of Hyperbaric Oxygen Therapy.
In this episode, we dive into how HBOT is a game-changer for inflammation. Harch explains that inflammation is the driving factor for countless chronic illnesses, but thankfully Hyperbaric Oxygen Therapy is a natural proven way to suppress inflammation.
Harch summarizes a fascinating study done in 2008, by Dr. Cassandra Godman. Her team took skin biopsies and extracted the normal tissue, then they examined the cells that lined the tiniest blood vessels in the tissue. Next, they put these cells in a petri dish and put them in a hyperbaric chamber and gave him a single hyperbaric treatment. Afterwards, they did a mass gene array analysis for 48 hours. What happened next was ground-breaking in better understanding the role that HBOT has on inflammation.
At the end of 24 hours 8,101 of our 19,000 protein coding genes in our 23 chromosomes were either significantly turned on or turned off & suppressed. That single HBOT treatment turned on the anti-inflammatory genes and the growth and repair hormone genes, and the largest cluster suppressed were the pro-inflammatory genes.
Our inflammatory reaction is inescapable when an injury occurs. But, when the patient receives hyperbaric oxygen therapy treatment after an injury (the sooner the better), it can have an overwhelming positive influence on the inflammatory reaction at any place along the spectrum. Harch continues to explain that the anti-inflammatory effects of hyperbaric oxygen are wide-ranging.
Harch spoke of the Navy’s experience with Hyperbaric Oxygen Therapy, as the Navy really kind of dominated this field for many years. The Navy reported that if you can get someone in a chamber within one hour of coming out of the water – when they’re symptomatic for decompression sickness – then the first hyperbaric treatment is curative in 90% of cases. Everyone thought that HBOT was treating bubbles in the brain at that point, but the reality is they were treating inflammation. We now know that it’s the inflammatory reaction in the brain after the bubbles passed that Hyperbaric Oxygen Therapy is treating; not the bubbles.
HBOT isn’t new, it dates back well over a hundred years. It’s still misunderstood, because many believe that HBOT therapy is a treatment for diseases. But, the reality is that HBOT is a treatment for disease processes, and it’s these processes that cause the diseases. We treat the inflammation that causes the disease processes, and in turn we treat the disease. That’s the power of Hyperbaric Oxygen Therapy.
Stay tuned for all nine episodes that will be release each Friday for the next eight weeks.
Guest
Dr. Paul G. Harch, MD
Dr. Paul G. Harch, M.D. is a clinician in emergency medicine and hyperbaric medicine who is the former director of the University Medical Center Hyperbaric Medicine Department and LSU Hyperbaric Medicine Fellowship. Currently, he is a Clinical Professor of Medicine in the Section of Emergency Medicine at LSU School of Medicine in New Orleans. He graduated from the Johns Hopkins University School of Medicine after graduating from the University of California at Irvine with magna cum laude/Phi Beta Kappa honors.
Dr. Harch initiated and continues to be a private practice that has resulted in the largest case experience in neurological hyperbaric medicine in the world. In this practice, he adapted the concepts of conventional hyperbaric oxygen therapy to wounds in the central nervous system, which spawned the subsequent academic and research practice. Harch HBOT is the best place to receive oxygen therapy treatments, and patients have traveled from more than 50 countries to be treated by Dr. Harch himself.
Harch HBOT – Hyperbaric Oxygen Therapy Clinic
5216 Lapalco Blvd.
Marrero, LA
504-309-4948
hbot@hbot.com
https://hbot.com/
Subscribe Now, It’s Free !
Recent HBOT News
The wound/burn guidelines – 3: Guidelines for the diagnosis and treatment for diabetic ulcer/gangrene.
Abstract: We aimed to prepare guidelines for the management of diabetic ulcer/gangrene with emphasis on the diagnosis and treatment of skin symptoms. They serve as a tool to improve the quality of the diagnosis and treatment in each patient and, further, to improve...
Clinical Trial – HBOT Global Functioning After Stroke
Stroke is one of the leading causes of disability and death in North America and Europe. Up
to 30% of stroke survivors never recuperate completely and suffer from loss of function and
poor quality of life. To improve recovery after stroke, innovative interventions should be a
priority.
Hyperbaric oxygen therapy (HBOT) is an intermittent inhalation of 100% oxygen in a hyperbaric
chamber at a pressure higher than 1 absolute atmosphere (ATA). There is a growing body of
evidence that HBOT can enhance ability of brain to changes its structure (neuroplasticity) in
order to recover. Exercise program during HBOT can augment the effect. Although, recent
randomized controlled trials in patients with chronic brain injury showed promising results,
there are no studies demonstrating combine effect HBOT and exercise rehabilitation program on
stroke recovery.
The proposed study investigates feasibility, safety and efficacy of using a combination of
HBOT and exercise program to improve arm function recovery in chronic stroke patients. In
this pilot randomized control trial, investigators will compare the combination of HBOT and
the focused rehabilitation exercise program versus exercise program alone on recovery of arm
function in patients with chronic stroke.
Clinical Trial – Hyperbaric Oxygen Therapy and Acute Kidney Injury
Kidney injury is a serious complication of cardiac surgery that occurs in up to 30% of
patients and increases the risk of adverse outcomes. Kidney injury initiates when oxygen
supply to the kidney drops below levels that are needed for normal cellular function, causing
tissue oxygen deficiency (hypoxia), activation of the inflammatory cascade, and oxidative
stress. Together, these events further impair tissue oxygenation, culminating in impaired
kidney function due to cellular injury and death.
There are no effective therapies for kidney injury after cardiac surgery, but there is
evidence that recovery is possible if the processes of injury – i.e., impaired oxygen
delivery, increased inflammatory response, and oxidative stress – are ameliorated soon after
the onset of injury. Hyperbaric oxygen therapy (HBOT) – which entails the intermittent
inhalation of 100% oxygen in a hyperbaric chamber at a pressure higher than one absolute
atmosphere (> 760 mmHg) – has been shown to positively affect all of these processes (i.e.,
to improve tissue oxygenation, reduce inflammation, and reduce oxidative stress). Thus, we
hypothesized that HBOT will reduce the severity of kidney injury after cardiac surgery if it
is initiated soon after onset of injury. This hypothesis has not been tested in humans, but
is supported by animal studies.
In this first-in-human, unblinded, controlled pilot trial, 20 adult patients who develop
severe kidney injury soon after cardiac surgery will be randomized (after obtaining informed
consent from the patient or surrogate) to standard-of-care or early HBOT. Severe kidney
injury will be defined as a ≥30% drop in kidney function within 6 hours of surgery (as
determined by change in creatinine from before surgery to Intensive Care Unit (ICU)
admission). This degree of injury occurs in ~ 2% of patients and is associated with a 12-fold
increase in the risk of complete kidney failure (requiring dialysis) or death. Patients will
be excluded if they have any relative or absolute contraindications to HBOT (e.g., severe
ventricular dysfunction, ventricular assist device, severe respiratory dysfunction,
pneumothorax, bronchospasm).